Decoding The Fiscal, Quality, And Social Architecture Of PMBJP

Manorama Bakshi
Arjun Kumar

For decades, a central criticism of India’s healthcare system was that while a medical diagnosis itself did not necessarily push families into bankruptcy, the subsequent cost of medicines often did. In a public health matrix where out-of-pocket expenditure (OOPE) historically constituted nearly 39% to 40% of total health spending, pharmaceuticals emerged as a regressive tax on the vulnerable. While insurance schemes like Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PM-JAY) have provided vital financial cushions for tertiary hospitalizations, the recurring costs of managing chronic conditions—through regular purchases of medicines for diabetes, hypertension, and cardiovascular diseases—have remained largely outside this safety net, leaving patients completely exposed to private retail price inflation.

It was this reality that drove the structural reinvention of the Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP). Originally launched in 2008 as the Jan Aushadhi Scheme, the initiative underwent a comprehensive operational and strategic overhaul, morphing into a powerful market intervention aimed at improving the affordability of essential medicines.

Administered by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers and implemented by the Pharmaceuticals and Medical Devices Bureau of India (PMBI), PMBJP serves as the government’s flagship initiative for expanding access to affordable generic medicines. Transitioning decisively past 18,000 functional Jan Aushadhi Kendras (JAKs) by early 2026, the mission has evolved well beyond a conventional welfare distribution model. It has structurally engineered a parallel pharmaceutical value chain, translating volume procurement into active economic empathy.

The Generics Conundrum: Quality, Perception, and Market Realities

The primary challenge to democratizing generic medicines in India has never been manufacturing capacity. India is widely recognised as the “pharmacy of the world,” producing around 60% of global vaccines and ranking third globally in pharmaceutical production by volume. The bottleneck has been an entrenched asymmetry in consumer perception and prescribing patterns. In the conventional retail market, the price of a drug is heavily decoupled from its baseline production cost, with brand premiums and extensive marketing contributing significantly to the final retail price. PMBJP is engineered to target this friction through two parallel mechanisms:

The Price Disconnect: Jan Aushadhi Kendras offer quality generic medicines at prices that are 50% to 90% cheaper than their branded market counterparts. For example, standard chronic medications like levocetirizine, a commonly prescribed medicine for allergies, retail at private counters for roughly ₹303, while a Jan Aushadhi center dispenses the equivalent therapeutic dose for a mere ₹13. Similarly, high-end critical care treatments, such as the oncology drug Imatinib Mesylate (400 mg), drop from a conventional retailer price of ₹1,952 down to just ₹210.
The Institutional Trust Protocol: Lower prices often raise concerns about quality. To address this, PMBI follows a stringent quality assurance process. According to official Press Information Bureau (PIB) frameworks, procurement is strictly restricted to WHO-GMP (Good Manufacturing Practices) compliant facilities, after which every single batch of medicine is independently tested at NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs before being released through the central distribution network.

The Multi-Tier Product Blueprint: Expanding the Therapeutic Basket

To effectively reduce out-of-pocket expenditure, a generic drug network must offer comprehensive therapeutic coverage. Over time, PMBJP has steadily expanded its product portfolio to minimise gaps in medicine availability across a wide range of health conditions.

The baseline of this expansion is built on an essential formulations grid featuring more than 2,110 high-quality generic medicines across 29 distinct therapeutic categories. This core medical inventory is structurally reinforced by a secondary rail of 315 high-grade surgical consumables and diagnostic instruments, enabling Jan Aushadhi Kendras to support a broader range of healthcare needs beyond dispensing medicines. The programme also incorporates an important preventive healthcare component through the distribution of Suvidha Oxo-Biodegradable Sanitary Pads at a heavily subsidised price of ₹1 per pad, improving access to affordable menstrual hygiene products.

The product portfolio now extends beyond essential medicines to include therapies for non-communicable diseases, chronic metabolic disorders, cancer treatment, and gastrointestinal care. By integrating medicines, medical devices, and surgical consumables within a single distribution network, the scheme enables both public institutions and private entrepreneurs to operate comprehensive community healthcare outlets.

Macro Scale and Economic Velocity: Accumulating National Savings

The programme’s impact is most evident in the scale of its expansion over the past decade. In 2014, PMBJP remained limited in scope, with just 84 functional Jan Aushadhi Kendras nationwide and a product portfolio of fewer than 300 essential medicines. As a result, its contribution to reducing out-of-pocket expenditure remained modest. By early 2026, however, the network had expanded to more than 18,000 functional Kendras, placing the programme within reach of its target of 25,000 Kendras by March 2027.

This physical expansion has created a high-velocity supply chain. Cumulative consumer savings over the past eleven years are estimated to be between ₹38,000 and ₹40,000 crore. Aggregate product sales, measured at maximum retail price (MRP), have exceeded ₹7,700 crore, while monthly sales now regularly surpass ₹200 crore. This growth has been supported by broader policy initiatives, including the ₹6,940 crore Production Linked Incentive (PLI) Scheme for Pharmaceuticals, which seeks to strengthen domestic production of active pharmaceutical ingredients (APIs) and enhance the resilience of India’s generic medicine supply chain against global disruptions.

On-Ground Expansion Framework and Regional Penetration

PMBJP’s expansion reflects a significant example of cooperative public-private implementation. Since the establishment and operation of Jan Aushadhi Kendras depend on local entrepreneurship and efficient logistics, the scheme has combined financial incentives with a franchise-based model to encourage wider participation. Pharmacists receive operating margins of 20%, along with a performance-linked incentive of up to ₹2.5 lakh (capped at ₹20,000 per month), based on sales recorded through the point-of-sale (POS) software, successfully aligning social policy with micro-entrepreneurship.

Furthermore, a one-time special incentive of ₹2 lakh, comprising ₹1.5 lakh for furniture and fixtures and ₹50,000 for digital infrastructure, is extended to women, SC/ST and Divyangjan entrepreneurs, as well as those establishing Kendras in NITI Aayog-notified Aspirational Districts, Himalayan regions, island territories, and the North-Eastern states.

The Transit Hub Integrations: To improve last-mile visibility, more than 116 Jan Aushadhi Kendras have been established at railway stations across the country. According to Press Information Bureau (PIB) data, these outlets serve high-footfall transit locations, improving access to affordable medicines for migrant workers, daily commuters, and low-income travellers.
The Urban Concentration Vectors: The national capital region of New Delhi highlights the programme’s urban expansion, scaling from just 4 Kendras in 2014 to hundreds of operational centres by early 2026, heavily anchored by high-volume areas such as Ashok Vihar, outer sub-districts, and other densely populated localities.
Difficult Terrain Trailblazers: Structural changes in states like Punjab, Jammu & Kashmir, and Himachal Pradesh demonstrate its ability to extend access to affordable medicines even in geographically challenging regions when backed by automated point-of-sale inventory synchronization.

A Reality Check on Execution: Supply-Chain and Prescribing Bottlenecks

Despite these strong structural and volume achievements, the everyday utilization of PMBJP faces persistent scaling challenges. These highlight the gap between building large-scale infrastructure and ensuring consistent last-mile access to affordable medicines.

Independent health policy research and media analyses point to a major implementation friction: the limited adoption of generic-name prescribing patterns among medical practitioners. Despite regulatory guidance encouraging generic prescriptions, many doctors in both the public and private sectors continue to prescribe branded medicines. When patients present branded prescriptions at a Jan Aushadhi Kendra, pharmacists are often legally or operationally constrained from substituting the prescribed medicine with its generic equivalent, limiting the scheme’s potential to reduce out-of-pocket expenditure.

Systemically, the supply chain faces three distinct obstacles. First are the regional stock-out vulnerabilities, where local outlets face periodic inventory gaps for high-demand medicines for chronic conditions. Second is the prescribing brand bias, driven by systemic physician hesitation to specify generic chemical nomenclatures. Third is the warehousing latency, which delays the transfer of drugs from large central hubs to decentralized retail outlets, affecting timely availability at the local level.

Furthermore, scaling a dynamic portfolio of items across thousands of franchise-operated stores introduces periodic inventory constraints. Media analysis points out that store financial viability remains tightly linked to strict inventory mandates. Under current PMBI criteria, a Kendra’s monthly performance incentive is directly prorated based on stocking depth, dropping down to a 50% payout if available inventory falls between 100 and 149 essential drugs. Because procurement remains centrally managed through regional warehouses, unexpected demand spikes for critical medicines such as anti-diabetics or anti-hypertensives can lead to temporary local stock shortages, forcing patients to purchase higher-priced alternatives from private pharmacies.

The Healthcare Complementarity Matrix

PMBJP does not operate in isolation; it operates as the primary cost buffer within India’s broader public healthcare strategy. While initiatives such as the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) focus on strengthening healthcare infrastructure, building out physical labs and Critical Care Blocks, and the Ayushman Bharat Digital Mission (ABDM) develops the country’s digital health ecosystem through more than 90 crore active ABHA IDs, PMBJP addresses one of the most immediate financial challenges faced by patients—the cost of medicines for day-to-day outpatient care.

Public health experts have consistently argued that the long-term effectiveness of health insurance schemes is constrained if prescription drug costs are left unmanaged. By making essential medicines more affordable, PMBJP complements programmes such as PM-JAY by reducing the financial burden that continues after hospital discharge. When a patient is discharged from an integrated critical care unit, their subsequent recovery and maintenance treatment can be handled through a Jan Aushadhi counter, preventing secondary health costs from driving families back toward financial distress.

The Social Impact Vectors: Sanitary Equity and Gender-Focused Care

Beyond the standard therapeutic categories, the structural framework of PMBJP has driven significant advancements in preventive health and gender equity. The prime example is the deployment of the Janaushadhi Suvidha Oxo-Biodegradable Sanitary Napkin.

Distributed through the national network of Jan Aushadhi Kendras at a subsidized price of ₹1 per pad, this initiative bypasses private commercial pricing to address menstrual hygiene challenges in rural and semi-urban communities. Official figures released during the Janaushadhi Saptah celebrations confirm that over 100 crore Suvidha sanitary pads have been sold through these Kendras. By making low-cost menstrual hygiene products widely accessible through an established pharmaceutical distribution system, the programme has integrated sanitary equity directly into a standard pharmaceutical logistics platform to dramatically lower the incidence of preventable reproductive infections among women and senior citizens.

The Strategic Way Ahead: Institutionalizing Prescription Trust

As PMBJP targets its next milestone of 25,000 operational Kendras by March 2027, the focus must shift from expanding the network to strengthening public confidence and supply chain consistency. The execution roadmap relies on three modern systemic enhancements: building out automated substitution rails to legally empower generic matching at the counter, deploying predictive cold-chain grids linked to multi-regional warehouse hubs, and advancing universal app synchronization to offer citizens real-time stock visibility across local stores.

First, India must strengthen regulatory compliance for generic prescribing. Hospital networks and state health departments should adopt automated electronic medical records (EMRs) that automatically default to generic molecular names rather than proprietary brand choices, helping to encourage more consistent generic prescribing practices.

Second, the central distribution infrastructure must be upgraded to meet modern logistics standards. Strengthening regional warehouses with automated inventory management and real-time stock monitoring can help minimise local shortages and improve the timely availability of essential medicines.

Finally, consumer access should be enhanced through digital tools. Actively linking the real-time stock availability data of individual Jan Aushadhi Kendras directly to the official “Jan Aushadhi Sugam” mobile application would allow citizens to check medicine availability before traveling, creating a highly transparent, user-friendly, and accessible public welfare grid.

Conclusion: The Immutable Base of Universal Equity

The true measure of a healthcare ecosystem’s maturity is ultimately its ability to protect citizens during their most vulnerable moments. India’s grand vision of a Viksit Bharat 2047 cannot rely solely on cutting-edge tertiary medical hubs; it must be built on a foundation of accessible, dignified, and affordable everyday care.

By decoupling the distribution of essential medicines from commercial brand inflation and expanding access to quality generic drugs, the Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana has emerged as a key pillar of India’s healthcare architecture. Complementing broader initiatives such as PM-JAY, PM-ABHIM, and the Ayushman Bharat Digital Mission, the scheme helps address one of the most persistent drivers of out-of-pocket expenditure. As the programme continues to expand, its long-term success will depend not only on the number of Kendras it establishes but also on its ability to strengthen public trust, ensure reliable medicine availability, and make affordable healthcare a consistent reality for millions of Indians.

About the Authors

Dr. Manorama Bakshi is Director & Head of Healthcare & Advocacy at Consocia Advisory, Founder & Director of the Triloki Raj Foundation, and a Senior Visiting Fellow at IMPRI.

Dr. Arjun Kumar is the Director of the IMPRI Impact and Policy Research Institute, New Delhi. He holds a Ph.D. in Economics from the Centre for the Study of Regional Development, School of Social Sciences, Jawaharlal Nehru University (JNU), New Delhi.

Disclaimer: All views expressed in the article belong solely to the author and not necessarily to the organisation.